– Quadria Capital, Asia’s premier healthcare-focused private equity firm, has announced the final close of Fund IIIwith US$1.07 billion in total commitments, surpassing its original $800 million target.
– The oversubscribed fundraise includes:
^ US$954 million in primary commitments
^ US$114 million in committed co-investment capital
^ US$300 million anticipated in additional co-investment capacity, bringing total capital to ~US$1.3 billion upon full deployment
– Fund III is 60% larger than Quadria’s previous $600 million fund (2020), making it the largest dedicated healthcare PE fund in South and Southeast Asia.
– Abrar Mir, Co-Founder and Managing Partner, Quadria Capital: “Fund III’s close, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission. It reflects deep global investor conviction in the transformational opportunity in Asian Healthcare, where social impact and financial performance go hand in hand.”
– Dr. Amit Varma, Co-Founder and Managing Partner, Quadria Capital: “Asia’s healthcare sector is at a pivotal moment, and it will remain in the limelight in 2025, especially with investment interest in India in areas like single-specialty hospitals, diagnostic chains, medical devices, and pharmaceutical manufacturing, which includes APIs and CDMOs.”
– Global investor backing includes:
^ Leading sovereign wealth funds, asset managers, and strategic corporates from North America and Europe
^ New commitments from institutions across the GCC (Saudi Arabia, UAE, Bahrain)
^ Participation from Indian banks, insurance companies, and family offices
Strong re-ups from impact investors
– Fund III positions Quadria to capture structural growth in Asia’s $5 trillion healthcare market, projected to drive 40% of global healthcare growth by 2030.
– Key focus areas for investment include:
^ Single-specialty hospitals
^ Diagnostic chains
^ Medical devices
^ Pharmaceutical manufacturing, including APIs and CDMOs
– Quadria sees 2025 and beyond as a “golden decade” for healthcare transformation driven by:
^ Rising healthcare consumption
^ Cost-efficiency measures
^ Technology integration
– Fund III aims to build a diversified portfolio of 10 companies, taking significant minority or majority stakes, and leveraging co-investments from LPs.
– Already 40% deployed, with investments in:
^ Aragen Life Sciences (global CRDMO)
^ NephroPlus (Asia’s largest dialysis chain)
^ Maxivision (India’s leading eye care chain)
– Two new investments in Southeast Asia are forthcoming
– Fund III continues Quadria’s track record of successful exits from previous funds, demonstrating investment discipline, operational expertise, and capital returns to investors.
– The oversubscribed fundraise includes:
^ US$954 million in primary commitments
^ US$114 million in committed co-investment capital
^ US$300 million anticipated in additional co-investment capacity, bringing total capital to ~US$1.3 billion upon full deployment
– Fund III is 60% larger than Quadria’s previous $600 million fund (2020), making it the largest dedicated healthcare PE fund in South and Southeast Asia.
– Abrar Mir, Co-Founder and Managing Partner, Quadria Capital: “Fund III’s close, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission. It reflects deep global investor conviction in the transformational opportunity in Asian Healthcare, where social impact and financial performance go hand in hand.”
– Dr. Amit Varma, Co-Founder and Managing Partner, Quadria Capital: “Asia’s healthcare sector is at a pivotal moment, and it will remain in the limelight in 2025, especially with investment interest in India in areas like single-specialty hospitals, diagnostic chains, medical devices, and pharmaceutical manufacturing, which includes APIs and CDMOs.”
– Global investor backing includes:
^ Leading sovereign wealth funds, asset managers, and strategic corporates from North America and Europe
^ New commitments from institutions across the GCC (Saudi Arabia, UAE, Bahrain)
^ Participation from Indian banks, insurance companies, and family offices
Strong re-ups from impact investors
– Fund III positions Quadria to capture structural growth in Asia’s $5 trillion healthcare market, projected to drive 40% of global healthcare growth by 2030.
– Key focus areas for investment include:
^ Single-specialty hospitals
^ Diagnostic chains
^ Medical devices
^ Pharmaceutical manufacturing, including APIs and CDMOs
– Quadria sees 2025 and beyond as a “golden decade” for healthcare transformation driven by:
^ Rising healthcare consumption
^ Cost-efficiency measures
^ Technology integration
– Fund III aims to build a diversified portfolio of 10 companies, taking significant minority or majority stakes, and leveraging co-investments from LPs.
– Already 40% deployed, with investments in:
^ Aragen Life Sciences (global CRDMO)
^ NephroPlus (Asia’s largest dialysis chain)
^ Maxivision (India’s leading eye care chain)
– Two new investments in Southeast Asia are forthcoming
– Fund III continues Quadria’s track record of successful exits from previous funds, demonstrating investment discipline, operational expertise, and capital returns to investors.